Skip to main content
Erschienen in: Current Infectious Disease Reports 3/2013

01.06.2013 | Pediatric Infectious Diseases (I Brook, Section Editor)

Probiotics and Prebiotics in Infants and Children

verfasst von: Y. Vandenplas, E. De Greef, T. Devreker, G. Veereman-Wauters, B. Hauser

Erschienen in: Current Infectious Disease Reports | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Probiotics and prebiotics have a major influence on gastrointestinal flora composition. This review analyses the relationship between this change in flora composition and health benefits in children. Literature databases were searched for relevant articles. Despite exhaustive research on the subject in different indications, such as prevention and treatment of acute gastroenteritis, antibiotic associated diarrhea (AAD), traveler's diarrhea, inflammatory bowel disease, irritable bowel syndrome, Helicobacter pylori, necrotizing enterocolitis, constipation, allergy and atopic dermatitis, colic and extraintestinal infections, reports of clear benefits for the use of prebiotics and probiotics in pediatric disorders remain scarce. The best evidence has been provided for the use of probiotics in acute gastroenteritis and in prevention of AAD. However, AAD in children is in general mild, and only seldom necessitates additional interventions. Overall, the duration of acute infectious diarrhea is reduced by approximately 24 hours. Evidence for clinically relevant benefit in all other indications (inflammatory bowel disease, irritable bowel syndrome, constipation, allergy) is weak to nonexistent. Selected probiotic strains given during late pregnancy and early infancy decrease atopic dermatitis. Adverse effects have very seldom been reported. Since the risk seems minimal to nonexistent, prebiotics and probiotics may be helpful in the prevention and treatment of some disorders in children, although the evidence for benefit is limited. The best evidence has been accumulated for some lactobacilli strains and for Saccharomyces boulardii in the reduction of the duration of acute diarrhea due to gastroenteritis and prevention of AAD.
Literatur
1.
Zurück zum Zitat Johnson CL, Versalovic J. The human microbiome and its potential importance to pediatrics. Pediatrics. 2012;129:950–60.PubMedCrossRef Johnson CL, Versalovic J. The human microbiome and its potential importance to pediatrics. Pediatrics. 2012;129:950–60.PubMedCrossRef
2.
Zurück zum Zitat •• Reid G. Microbiology: Categorize probiotics to speed research. Nature. 2012;485:446. Classifies different probiotic products and proposes minimal requirements for claims.PubMedCrossRef •• Reid G. Microbiology: Categorize probiotics to speed research. Nature. 2012;485:446. Classifies different probiotic products and proposes minimal requirements for claims.PubMedCrossRef
3.
Zurück zum Zitat Ritchie ML, Romanuk TN. A meta-analysis of probiotic efficacy for gastrointestinal diseases. PLoS One. 2012;7:e34938.PubMedCrossRef Ritchie ML, Romanuk TN. A meta-analysis of probiotic efficacy for gastrointestinal diseases. PLoS One. 2012;7:e34938.PubMedCrossRef
4.
Zurück zum Zitat Vandenplas Y. Identification of probiotics by specific strain name. Aliment Pharmacol Ther. 2012;35:860.CrossRef Vandenplas Y. Identification of probiotics by specific strain name. Aliment Pharmacol Ther. 2012;35:860.CrossRef
5.
Zurück zum Zitat Bicer S, Sahin GT, Koncay B, et al. Incidence assessment of rotavirus and adenovirus associated acute gastroenteritis cases in early childhood. Infez Med. 2011;19:113–9.PubMed Bicer S, Sahin GT, Koncay B, et al. Incidence assessment of rotavirus and adenovirus associated acute gastroenteritis cases in early childhood. Infez Med. 2011;19:113–9.PubMed
6.
Zurück zum Zitat Muhsen K, Shulman L, Rubinstein U, et al. TAU-HCLV Rota Study Group. Incidence, characteristics, and economic burden of rotavirus gastroenteritis associated with hospitalization of Israeli children <5 years of age, 2007–2008. J Infect Dis. 2009;200 Suppl 1:S254–63.PubMedCrossRef Muhsen K, Shulman L, Rubinstein U, et al. TAU-HCLV Rota Study Group. Incidence, characteristics, and economic burden of rotavirus gastroenteritis associated with hospitalization of Israeli children <5 years of age, 2007–2008. J Infect Dis. 2009;200 Suppl 1:S254–63.PubMedCrossRef
7.
Zurück zum Zitat Goldman AS. Evolution of immune functions of the mammary gland and protection of the infant. Breastfeed Med. 2012;7:132–42.PubMedCrossRef Goldman AS. Evolution of immune functions of the mammary gland and protection of the infant. Breastfeed Med. 2012;7:132–42.PubMedCrossRef
8.
Zurück zum Zitat Martín V, Maldonado-Barragán A, Moles L, et al. Sharing of bacterial strains between breast milk and infant feces. J Hum Lact. 2012;28:36–44.PubMedCrossRef Martín V, Maldonado-Barragán A, Moles L, et al. Sharing of bacterial strains between breast milk and infant feces. J Hum Lact. 2012;28:36–44.PubMedCrossRef
9.
Zurück zum Zitat Totten SM, Zivkovic AM, Wu S, et al. Comprehensive profiles of human milk oligosaccharides yield highly sensitive and specific markers for determining secretor status in lactating mothers. J Proteome Res. 2012;11:6124–33.PubMed Totten SM, Zivkovic AM, Wu S, et al. Comprehensive profiles of human milk oligosaccharides yield highly sensitive and specific markers for determining secretor status in lactating mothers. J Proteome Res. 2012;11:6124–33.PubMed
10.
Zurück zum Zitat Agustina R, Kok FJ, van de Rest O, et al. Randomized trial of probiotics and calcium on diarrhea and respiratory tract infections in Indonesian children. Pediatrics. 2012;129:e1155–64.PubMedCrossRef Agustina R, Kok FJ, van de Rest O, et al. Randomized trial of probiotics and calcium on diarrhea and respiratory tract infections in Indonesian children. Pediatrics. 2012;129:e1155–64.PubMedCrossRef
11.
Zurück zum Zitat Guandalini S. Probiotics for prevention and treatment of diarrhea. J Clin Gastroenterol. 2011;45(Suppl):S149–53.PubMedCrossRef Guandalini S. Probiotics for prevention and treatment of diarrhea. J Clin Gastroenterol. 2011;45(Suppl):S149–53.PubMedCrossRef
12.
Zurück zum Zitat Wanke M, Szajewska H. Lack of an effect of Lactobacillus reuteri DSM 17938 in preventing nosocomial diarrhea in children: a randomized, double-blind, placebo-controlled trial. J Pediatr. 2012;161:40–3.PubMedCrossRef Wanke M, Szajewska H. Lack of an effect of Lactobacillus reuteri DSM 17938 in preventing nosocomial diarrhea in children: a randomized, double-blind, placebo-controlled trial. J Pediatr. 2012;161:40–3.PubMedCrossRef
13.
Zurück zum Zitat Gil-Campos M, López MÁ, Rodriguez-Benítez MV, et al. Lactobacillus fermentum CECT 5716 is safe and well tolerated in infants of 1–6 months of age: a randomized controlled trial. Pharmacol Res. 2012;65:231–8.PubMedCrossRef Gil-Campos M, López MÁ, Rodriguez-Benítez MV, et al. Lactobacillus fermentum CECT 5716 is safe and well tolerated in infants of 1–6 months of age: a randomized controlled trial. Pharmacol Res. 2012;65:231–8.PubMedCrossRef
14.
Zurück zum Zitat • Braegger C, Chmielewska A, Decsi T, et al. ESPGHAN Committee on Nutrition. Supplementation of infant formula with probiotics and/or prebiotics: a systematic review and comment by the ESPGHAN Committee on Nutrition. J Pediatr Gastroenterol Nutr. 2011;52:238–50. An ESPGHAN position paper on (the poor evidence of benefit of) pre- and probiotics added to infant formula.PubMedCrossRef • Braegger C, Chmielewska A, Decsi T, et al. ESPGHAN Committee on Nutrition. Supplementation of infant formula with probiotics and/or prebiotics: a systematic review and comment by the ESPGHAN Committee on Nutrition. J Pediatr Gastroenterol Nutr. 2011;52:238–50. An ESPGHAN position paper on (the poor evidence of benefit of) pre- and probiotics added to infant formula.PubMedCrossRef
15.
Zurück zum Zitat Thomas DW, Greer FR. Clinical report: probiotics and prebiotics in pediatrics. Pediatrics. 2010;126:1217–31.PubMedCrossRef Thomas DW, Greer FR. Clinical report: probiotics and prebiotics in pediatrics. Pediatrics. 2010;126:1217–31.PubMedCrossRef
16.
Zurück zum Zitat Bruzzese E, Volpicelli M, Squeglia V, et al. A formula containing galacto- and fructo-oligosaccharides prevents intestinal and extra-intestinal infections: an observational study. Clin Nutr. 2009;28:156–61.PubMedCrossRef Bruzzese E, Volpicelli M, Squeglia V, et al. A formula containing galacto- and fructo-oligosaccharides prevents intestinal and extra-intestinal infections: an observational study. Clin Nutr. 2009;28:156–61.PubMedCrossRef
17.
Zurück zum Zitat • Guarino A, Dupont C, Gorelov AV, et al. The management of acute diarrhea in children in developed and developing areas: from evidence base to clinical practice. Expert Opin Pharmacother. 2012;13:17–26. For the first time, the socio-economic impact of decreasing the duration of diarrhea with 24 hours is recognized as important.PubMedCrossRef • Guarino A, Dupont C, Gorelov AV, et al. The management of acute diarrhea in children in developed and developing areas: from evidence base to clinical practice. Expert Opin Pharmacother. 2012;13:17–26. For the first time, the socio-economic impact of decreasing the duration of diarrhea with 24 hours is recognized as important.PubMedCrossRef
18.
Zurück zum Zitat Francavilla R, Lionetti E, Castellaneta S, et al. Randomised clinical trial: Lactobacillus reuteri DSM 17938 vs. placebo in children with acute diarrhoea – a double-blind study. Aliment Pharmacol Ther. 2012;36:363–9.PubMedCrossRef Francavilla R, Lionetti E, Castellaneta S, et al. Randomised clinical trial: Lactobacillus reuteri DSM 17938 vs. placebo in children with acute diarrhoea – a double-blind study. Aliment Pharmacol Ther. 2012;36:363–9.PubMedCrossRef
19.
Zurück zum Zitat Sarker SA, Sultana S, Fuchs GJ, et al. Lactobacillus paracasei strain ST11 has no effect on rotavirus but ameliorates the outcome of nonrotavirus diarrhea in children from Bangladesh. Pediatrics. 2005;116:e221–8.PubMedCrossRef Sarker SA, Sultana S, Fuchs GJ, et al. Lactobacillus paracasei strain ST11 has no effect on rotavirus but ameliorates the outcome of nonrotavirus diarrhea in children from Bangladesh. Pediatrics. 2005;116:e221–8.PubMedCrossRef
20.
Zurück zum Zitat Muñoz JA, Chenoll E, Casinos B, et al. Novel probiotic Bifidobacterium longum subsp. infantis CECT 7210 strain active against rotavirus infections. Appl Environ Microbiol. 2011;77:8775–83.PubMedCrossRef Muñoz JA, Chenoll E, Casinos B, et al. Novel probiotic Bifidobacterium longum subsp. infantis CECT 7210 strain active against rotavirus infections. Appl Environ Microbiol. 2011;77:8775–83.PubMedCrossRef
21.
Zurück zum Zitat Riaz M, Alam S, Malik A, Ali SM. Efficacy and safety of Saccharomyces boulardii in acute childhood diarrhea: a double blind randomised controlled trial. Indian J Pediatr. 2012;79:478–82.PubMedCrossRef Riaz M, Alam S, Malik A, Ali SM. Efficacy and safety of Saccharomyces boulardii in acute childhood diarrhea: a double blind randomised controlled trial. Indian J Pediatr. 2012;79:478–82.PubMedCrossRef
22.
Zurück zum Zitat Allen SJ, Martinez EG, Gregorio GV, Dans LF. Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev. 2010;11, CD003048.PubMed Allen SJ, Martinez EG, Gregorio GV, Dans LF. Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev. 2010;11, CD003048.PubMed
23.
Zurück zum Zitat Churgay CA, Aftab Z. Gastroenteritis in children: Part II. Prevention and management. Am Fam Physician. 2012;85:1066–70.PubMed Churgay CA, Aftab Z. Gastroenteritis in children: Part II. Prevention and management. Am Fam Physician. 2012;85:1066–70.PubMed
24.
Zurück zum Zitat Vandenplas Y. De Hert S; Probiotical study group. Cost/benefit of synbiotics in acute infectious gastroenteritis: spend to save. Benef Microbes. 2012;3:189–94.PubMedCrossRef Vandenplas Y. De Hert S; Probiotical study group. Cost/benefit of synbiotics in acute infectious gastroenteritis: spend to save. Benef Microbes. 2012;3:189–94.PubMedCrossRef
25.
Zurück zum Zitat Hoekstra JH, Szajewska H, Zikri MA, et al. Oral rehydration solution containing a mixture of non-digestible carbohydrates in the treatment of acute diarrhea: a multicenter randomized placebo controlled study on behalf of the ESPGHAN working group on intestinal infections. J Pediatr Gastroenterol Nutr. 2004;39:239–45.PubMedCrossRef Hoekstra JH, Szajewska H, Zikri MA, et al. Oral rehydration solution containing a mixture of non-digestible carbohydrates in the treatment of acute diarrhea: a multicenter randomized placebo controlled study on behalf of the ESPGHAN working group on intestinal infections. J Pediatr Gastroenterol Nutr. 2004;39:239–45.PubMedCrossRef
26.
Zurück zum Zitat Passariello A, Terrin G, De Marco G, et al. Efficacy of a new hypotonic oral rehydration solution containing zinc and prebiotics in the treatment of childhood acute diarrhea: a randomized controlled trial. J Pediatr. 2011;158:288–92.PubMedCrossRef Passariello A, Terrin G, De Marco G, et al. Efficacy of a new hypotonic oral rehydration solution containing zinc and prebiotics in the treatment of childhood acute diarrhea: a randomized controlled trial. J Pediatr. 2011;158:288–92.PubMedCrossRef
27.
Zurück zum Zitat Passariello A, Terrin G, Cecere G, et al. Randomised clinical trial: efficacy of a new synbiotic formulation containing Lactobacillus paracasei B21060 plus arabinogalactan and xilooligosaccharides in children with acute diarrhoea. Aliment Pharmacol Ther. 2012;35:782–8.PubMedCrossRef Passariello A, Terrin G, Cecere G, et al. Randomised clinical trial: efficacy of a new synbiotic formulation containing Lactobacillus paracasei B21060 plus arabinogalactan and xilooligosaccharides in children with acute diarrhoea. Aliment Pharmacol Ther. 2012;35:782–8.PubMedCrossRef
28.
Zurück zum Zitat Vandenplas Y. De Hert SG; PROBIOTICAL-study group. Randomised clinical trial: the synbiotic food supplement Probiotical vs. placebo for acute gastroenteritis in children. Aliment Pharmacol Ther. 2011;34:862–7.PubMedCrossRef Vandenplas Y. De Hert SG; PROBIOTICAL-study group. Randomised clinical trial: the synbiotic food supplement Probiotical vs. placebo for acute gastroenteritis in children. Aliment Pharmacol Ther. 2011;34:862–7.PubMedCrossRef
29.
Zurück zum Zitat Pieścik-Lech M, Shamir R, Guarino A, Szajewska H. Review article: the management of acute gastroenteritis in children. Aliment Pharmacol Ther. 2013;37:289–303.PubMedCrossRef Pieścik-Lech M, Shamir R, Guarino A, Szajewska H. Review article: the management of acute gastroenteritis in children. Aliment Pharmacol Ther. 2013;37:289–303.PubMedCrossRef
30.
Zurück zum Zitat Hempel S, Newberry SJ, Maher AR, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA. 2012;307:1959–69.PubMedCrossRef Hempel S, Newberry SJ, Maher AR, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA. 2012;307:1959–69.PubMedCrossRef
31.
Zurück zum Zitat Videlock EJ, Cremonini F. Meta-analysis: probiotics in antibiotic-associated diarrhoea. Aliment Pharmacol Ther. 2012;35:1355–69.PubMedCrossRef Videlock EJ, Cremonini F. Meta-analysis: probiotics in antibiotic-associated diarrhoea. Aliment Pharmacol Ther. 2012;35:1355–69.PubMedCrossRef
32.
Zurück zum Zitat Sazawal S, Hiremath G, Dhingra U, et al. Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomised, placebo-controlled trials. Lancet Infect Dis. 2006;6:374–82.PubMedCrossRef Sazawal S, Hiremath G, Dhingra U, et al. Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomised, placebo-controlled trials. Lancet Infect Dis. 2006;6:374–82.PubMedCrossRef
33.
Zurück zum Zitat •• Johnston BC, Goldenberg JZ, Vandvik PO, et al. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2011;11:CD004827. An excellent meta-analysis showing efficacy of selected probiotic strains in the prevention of antibiotic-associated diarrhea.PubMed •• Johnston BC, Goldenberg JZ, Vandvik PO, et al. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2011;11:CD004827. An excellent meta-analysis showing efficacy of selected probiotic strains in the prevention of antibiotic-associated diarrhea.PubMed
34.
Zurück zum Zitat Pozzoni P, Riva A, Bellatorre AG, et al. Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea in adult hospitalized patients: a single-center, randomized, double-blind, placebo-controlled trial. Am J Gastroenterol. 2012;107:922–31.PubMedCrossRef Pozzoni P, Riva A, Bellatorre AG, et al. Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea in adult hospitalized patients: a single-center, randomized, double-blind, placebo-controlled trial. Am J Gastroenterol. 2012;107:922–31.PubMedCrossRef
35.
Zurück zum Zitat Friedman G. The role of probiotics in the prevention and treatment of antibiotic-associated diarrhea and Clostridium difficile colitis. Gastroenterol Clin North Am. 2012;41:763–79.PubMedCrossRef Friedman G. The role of probiotics in the prevention and treatment of antibiotic-associated diarrhea and Clostridium difficile colitis. Gastroenterol Clin North Am. 2012;41:763–79.PubMedCrossRef
36.
Zurück zum Zitat Cremonini F, Videlock EJ. Probiotics are associated with a decreased risk of antibiotic-associated diarrhoea. Evid Based Med. 2013;18:71–2.PubMedCrossRef Cremonini F, Videlock EJ. Probiotics are associated with a decreased risk of antibiotic-associated diarrhoea. Evid Based Med. 2013;18:71–2.PubMedCrossRef
37.
Zurück zum Zitat ESPGHAN Working Group on Probiotics and Prebiotics, Szajewska H, Weizman Z, Abu-Zekry M, et al. Inulin and fructo-oligosaccharides for the prevention of antibiotic-associated diarrhea in children: report by the ESPGHAN Working Group on Probiotics and Prebiotics. J Pediatr Gastroenterol Nutr. 2012;54:828–9.PubMedCrossRef ESPGHAN Working Group on Probiotics and Prebiotics, Szajewska H, Weizman Z, Abu-Zekry M, et al. Inulin and fructo-oligosaccharides for the prevention of antibiotic-associated diarrhea in children: report by the ESPGHAN Working Group on Probiotics and Prebiotics. J Pediatr Gastroenterol Nutr. 2012;54:828–9.PubMedCrossRef
38.
Zurück zum Zitat •• Vanhee LM, Goemé F, Nelis HJ, Coenye T. Quality control of fifteen probiotic products containing Saccharomyces boulardii. J Appl Microbiol. 2010;109:1745–52. A nice study showing that what matters are commercial products, not strains. Clinical studies should be performed with the commercial product.PubMed •• Vanhee LM, Goemé F, Nelis HJ, Coenye T. Quality control of fifteen probiotic products containing Saccharomyces boulardii. J Appl Microbiol. 2010;109:1745–52. A nice study showing that what matters are commercial products, not strains. Clinical studies should be performed with the commercial product.PubMed
40.
Zurück zum Zitat DuPont HL, Ericsson CD, Farthing MJ, et al. Expert review of the evidence base for prevention of travelers' diarrhea. J Travel Med. 2009;16:149–60.PubMedCrossRef DuPont HL, Ericsson CD, Farthing MJ, et al. Expert review of the evidence base for prevention of travelers' diarrhea. J Travel Med. 2009;16:149–60.PubMedCrossRef
41.
Zurück zum Zitat Kollaritsch H, Paulke-Korinek M, Wiedermann U. Traveler's diarrhea. Infect Dis Clin North Am. 2012;26:691–706.PubMedCrossRef Kollaritsch H, Paulke-Korinek M, Wiedermann U. Traveler's diarrhea. Infect Dis Clin North Am. 2012;26:691–706.PubMedCrossRef
42.
Zurück zum Zitat Oliva S, Di Nardo G, Ferrari F, et al. Randomised clinical trial: the effectiveness of Lactobacillus reuteri ATCC 55730 rectal enema in children with active distal ulcerative colitis. Aliment Pharmacol Ther. 2012;35:327–34.PubMedCrossRef Oliva S, Di Nardo G, Ferrari F, et al. Randomised clinical trial: the effectiveness of Lactobacillus reuteri ATCC 55730 rectal enema in children with active distal ulcerative colitis. Aliment Pharmacol Ther. 2012;35:327–34.PubMedCrossRef
43.
Zurück zum Zitat Miele E, Pascarella F, Giannetti E, et al. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol. 2009;104:437–43.PubMedCrossRef Miele E, Pascarella F, Giannetti E, et al. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol. 2009;104:437–43.PubMedCrossRef
44.
Zurück zum Zitat Whelan K, Quigley EM. Probiotics in the management of irritable bowel syndrome and inflammatory bowel disease. Curr Opin Gastroenterol. 2013;29:184–9.PubMedCrossRef Whelan K, Quigley EM. Probiotics in the management of irritable bowel syndrome and inflammatory bowel disease. Curr Opin Gastroenterol. 2013;29:184–9.PubMedCrossRef
45.
Zurück zum Zitat Jonkers D, Penders J, Masclee A, Pierik M. Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients. Drugs. 2012;72:803–23.PubMedCrossRef Jonkers D, Penders J, Masclee A, Pierik M. Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients. Drugs. 2012;72:803–23.PubMedCrossRef
46.
Zurück zum Zitat • Fedorak R, Demeria D. Probiotic bacteria in the prevention and the treatment of inflammatory bowel disease. Gastroenterol Clin North Am. 2012;41:821–42. Although relating mainly to adults, this overview shows the (lack of ) evidence of probiotics in inflammatory bowel disease.PubMedCrossRef • Fedorak R, Demeria D. Probiotic bacteria in the prevention and the treatment of inflammatory bowel disease. Gastroenterol Clin North Am. 2012;41:821–42. Although relating mainly to adults, this overview shows the (lack of ) evidence of probiotics in inflammatory bowel disease.PubMedCrossRef
47.
Zurück zum Zitat Park KT, Perez F, Tsai R, et al. Cost-effectiveness analysis of adjunct VSL#3 therapy versus standard medical therapy in pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr. 2011;53:489–96.PubMed Park KT, Perez F, Tsai R, et al. Cost-effectiveness analysis of adjunct VSL#3 therapy versus standard medical therapy in pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr. 2011;53:489–96.PubMed
48.
Zurück zum Zitat Huertas-Ceballos AA, Logan S, Bennett C, Macarthur C. Dietary interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood. Cochrane Database Syst Rev. 2009;1, CD003019.PubMed Huertas-Ceballos AA, Logan S, Bennett C, Macarthur C. Dietary interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood. Cochrane Database Syst Rev. 2009;1, CD003019.PubMed
49.
Zurück zum Zitat Francavilla R, Miniello V, Magistà AM, et al. A randomized controlled trial of Lactobacillus GG in children with functional abdominal pain. Pediatrics. 2010;126:e1445–52.PubMedCrossRef Francavilla R, Miniello V, Magistà AM, et al. A randomized controlled trial of Lactobacillus GG in children with functional abdominal pain. Pediatrics. 2010;126:e1445–52.PubMedCrossRef
50.
Zurück zum Zitat Horvath A, Dziechciarz P, Szajewska H. Meta-analysis: Lactobacillus rhamnosus GG for abdominal pain-related functional gastrointestinal disorders in childhood. Aliment Pharmacol Ther. 2011;33:1302–10.PubMedCrossRef Horvath A, Dziechciarz P, Szajewska H. Meta-analysis: Lactobacillus rhamnosus GG for abdominal pain-related functional gastrointestinal disorders in childhood. Aliment Pharmacol Ther. 2011;33:1302–10.PubMedCrossRef
51.
Zurück zum Zitat Vivatvakin B, Mahayosnond A, Theamboonlers A, et al. Effect of a whey-predominant starter formula containing LCPUFAs and oligosaccharides (FOS/GOS) on gastrointestinal comfort in infants. Asia Pac J Clin Nutr. 2010;19:473–80.PubMed Vivatvakin B, Mahayosnond A, Theamboonlers A, et al. Effect of a whey-predominant starter formula containing LCPUFAs and oligosaccharides (FOS/GOS) on gastrointestinal comfort in infants. Asia Pac J Clin Nutr. 2010;19:473–80.PubMed
52.
Zurück zum Zitat Khoshoo V, Sun SS, Storm H. Tolerance of an enteral formula with insoluble and prebiotic fiber in children with compromised gastrointestinal function. J Am Diet Assoc. 2010;110:1728–33.PubMedCrossRef Khoshoo V, Sun SS, Storm H. Tolerance of an enteral formula with insoluble and prebiotic fiber in children with compromised gastrointestinal function. J Am Diet Assoc. 2010;110:1728–33.PubMedCrossRef
53.
Zurück zum Zitat Lionetti E, Indrio F, Pavone L, et al. Role of probiotics in pediatric patients with Helicobacter pylori infection: a comprehensive review of the literature. Helicobacter. 2010;15:79–87.PubMedCrossRef Lionetti E, Indrio F, Pavone L, et al. Role of probiotics in pediatric patients with Helicobacter pylori infection: a comprehensive review of the literature. Helicobacter. 2010;15:79–87.PubMedCrossRef
54.
Zurück zum Zitat Kindermann A, Lopes AI. Helicobacter pylori infection in pediatrics. Helicobacter. 2009;14 Suppl 1:52–7.PubMedCrossRef Kindermann A, Lopes AI. Helicobacter pylori infection in pediatrics. Helicobacter. 2009;14 Suppl 1:52–7.PubMedCrossRef
55.
Zurück zum Zitat Lionetti E, Francavilla R, Castellazzi AM, et al. Probiotics and helicobacter pylori infection in children. J Biol Regul Homeost Agents. 2012;26(1 Suppl):69–76. Lionetti E, Francavilla R, Castellazzi AM, et al. Probiotics and helicobacter pylori infection in children. J Biol Regul Homeost Agents. 2012;26(1 Suppl):69–76.
56.
Zurück zum Zitat Lin WH, Lin CK, Sheu SJ, et al. Antagonistic activity of spent culture supernatants of lactic acid bacteria against Helicobacter pylori growth and infection in human gastric epithelial AGS cells. J Food Sci. 2009;74:225–30.CrossRef Lin WH, Lin CK, Sheu SJ, et al. Antagonistic activity of spent culture supernatants of lactic acid bacteria against Helicobacter pylori growth and infection in human gastric epithelial AGS cells. J Food Sci. 2009;74:225–30.CrossRef
57.
Zurück zum Zitat Yang YJ, Sheu BS. Probiotics-containing yogurts suppress Helicobacter pylori load and modify immune response and intestinal microbiota in the Helicobacter pylori-infected children. Helicobacter. 2012;17:297–304.PubMedCrossRef Yang YJ, Sheu BS. Probiotics-containing yogurts suppress Helicobacter pylori load and modify immune response and intestinal microbiota in the Helicobacter pylori-infected children. Helicobacter. 2012;17:297–304.PubMedCrossRef
58.
Zurück zum Zitat Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther. 2010;32:1069–79.PubMedCrossRef Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther. 2010;32:1069–79.PubMedCrossRef
59.
Zurück zum Zitat • Malfertheiner P, Selgrad M, Bornschein J. Helicobacter pylori: clinical management. Curr Opin Gastroenterol. 2012;28:608–14. Many probiotics increase the eradication efficacy of standard treatment by about 10 %.PubMedCrossRef • Malfertheiner P, Selgrad M, Bornschein J. Helicobacter pylori: clinical management. Curr Opin Gastroenterol. 2012;28:608–14. Many probiotics increase the eradication efficacy of standard treatment by about 10 %.PubMedCrossRef
60.
Zurück zum Zitat Wilhelm SM, Johnson JL, Kale-Pradhan PB. Treating bugs with bugs: the role of probiotics as adjunctive therapy for Helicobacter pylori. Ann Pharmacother. 2011;45:960–6.PubMedCrossRef Wilhelm SM, Johnson JL, Kale-Pradhan PB. Treating bugs with bugs: the role of probiotics as adjunctive therapy for Helicobacter pylori. Ann Pharmacother. 2011;45:960–6.PubMedCrossRef
61.
Zurück zum Zitat Hoyos AB. Reduced incidence of necrotizing enterocolitis associated with enteral administration of Lactobacillus acidophilus and Bifidobacterium infantis to neonates in an intensive care unit. Int J Infect Dis. 1999;3:197–202.PubMedCrossRef Hoyos AB. Reduced incidence of necrotizing enterocolitis associated with enteral administration of Lactobacillus acidophilus and Bifidobacterium infantis to neonates in an intensive care unit. Int J Infect Dis. 1999;3:197–202.PubMedCrossRef
62.
Zurück zum Zitat Alfaleh K, Anabrees J, Bassler D, Al-Kharfi T. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev. 2011;3, CD005496.PubMed Alfaleh K, Anabrees J, Bassler D, Al-Kharfi T. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev. 2011;3, CD005496.PubMed
63.
Zurück zum Zitat Downard CD, Renaud E, St Peter SD, et al. 2012 American Pediatric Surgical Association Outcomes Clinical Trials Committee. Treatment of necrotizing enterocolitis: an American Pediatric Surgical Association Outcomes and Clinical Trials Committee systematic review. J Pediatr Surg. 2012;47:2111–22.PubMedCrossRef Downard CD, Renaud E, St Peter SD, et al. 2012 American Pediatric Surgical Association Outcomes Clinical Trials Committee. Treatment of necrotizing enterocolitis: an American Pediatric Surgical Association Outcomes and Clinical Trials Committee systematic review. J Pediatr Surg. 2012;47:2111–22.PubMedCrossRef
64.
Zurück zum Zitat •• Mihatsch WA, Braegger CP, Decsi T, et al. Critical systematic review of the level of evidence for routine use of probiotics for reduction of mortality and prevention of necrotizing enterocolitis and sepsis in preterm infants. Clin Nutr. 2012;31:6–15. The efficacy of probiotics on the prevention of NEC is put in its right perspective.PubMedCrossRef •• Mihatsch WA, Braegger CP, Decsi T, et al. Critical systematic review of the level of evidence for routine use of probiotics for reduction of mortality and prevention of necrotizing enterocolitis and sepsis in preterm infants. Clin Nutr. 2012;31:6–15. The efficacy of probiotics on the prevention of NEC is put in its right perspective.PubMedCrossRef
65.
Zurück zum Zitat •• Janvier A, Lantos J, Barrington K. The politics of probiotics: probiotics, necrotizing enterocolitis, and the ethics of neonatal research. Acta Paediatr. 2013;102:116–8. These authors have a different opinion from Mihatsch et al. The debate "probiotic or not" in the prevention of necrotizing enterocolitis is open.PubMedCrossRef •• Janvier A, Lantos J, Barrington K. The politics of probiotics: probiotics, necrotizing enterocolitis, and the ethics of neonatal research. Acta Paediatr. 2013;102:116–8. These authors have a different opinion from Mihatsch et al. The debate "probiotic or not" in the prevention of necrotizing enterocolitis is open.PubMedCrossRef
66.
Zurück zum Zitat Szajewska H. Probiotics and prebiotics in preterm infants: where are we? Where are we going? Early Hum Dev. 2010;86 Suppl 1:81–6.PubMedCrossRef Szajewska H. Probiotics and prebiotics in preterm infants: where are we? Where are we going? Early Hum Dev. 2010;86 Suppl 1:81–6.PubMedCrossRef
67.
Zurück zum Zitat Tabbers MM, de Milliano I, Roseboom MG, Benninga MA. Is Bifidobacterium breve effective in the treatment of childhood constipation? Results from a pilot study. Nutr J. 2011;10:19.PubMedCrossRef Tabbers MM, de Milliano I, Roseboom MG, Benninga MA. Is Bifidobacterium breve effective in the treatment of childhood constipation? Results from a pilot study. Nutr J. 2011;10:19.PubMedCrossRef
68.
Zurück zum Zitat Coccorullo P, Strisciuglio C, Martinelli M, et al. Lactobacillus reuteri (DSM 17938) in infants with functional chronic constipation: a double-blind, randomized, placebo-controlled study. J Pediatr. 2010;157:598–602.PubMedCrossRef Coccorullo P, Strisciuglio C, Martinelli M, et al. Lactobacillus reuteri (DSM 17938) in infants with functional chronic constipation: a double-blind, randomized, placebo-controlled study. J Pediatr. 2010;157:598–602.PubMedCrossRef
69.
Zurück zum Zitat Guerra PV, Lima LN, Souza TC, et al. Pediatric functional constipation treatment with Bifidobacterium-containing yogurt: a crossover, double-blind, controlled trial. World J Gastroenterol. 2011;17:3916–21.PubMedCrossRef Guerra PV, Lima LN, Souza TC, et al. Pediatric functional constipation treatment with Bifidobacterium-containing yogurt: a crossover, double-blind, controlled trial. World J Gastroenterol. 2011;17:3916–21.PubMedCrossRef
70.
Zurück zum Zitat Tabbers MM, Chmielewska A, Roseboom MG, et al. Fermented milk containing Bifidobacterium lactis DN-173 010 in childhood constipation: a randomized, double-blind, controlled trial. Pediatrics. 2011;127:e1392–9.PubMedCrossRef Tabbers MM, Chmielewska A, Roseboom MG, et al. Fermented milk containing Bifidobacterium lactis DN-173 010 in childhood constipation: a randomized, double-blind, controlled trial. Pediatrics. 2011;127:e1392–9.PubMedCrossRef
71.
Zurück zum Zitat Tabbers MM, Boluyt N, Berger MY, Benninga MA. Nonpharmacologic treatments for childhood constipation: systematic review. Pediatrics. 2011;128:753–61.PubMedCrossRef Tabbers MM, Boluyt N, Berger MY, Benninga MA. Nonpharmacologic treatments for childhood constipation: systematic review. Pediatrics. 2011;128:753–61.PubMedCrossRef
72.
Zurück zum Zitat Schouten B, Van Esch BC, Kormelink TG, et al. Non-digestible oligosaccharides reduce immunoglobulin free light-chain concentrations in infants at risk for allergy. Pediatr Allergy Immunol. 2011;22:537–42.PubMedCrossRef Schouten B, Van Esch BC, Kormelink TG, et al. Non-digestible oligosaccharides reduce immunoglobulin free light-chain concentrations in infants at risk for allergy. Pediatr Allergy Immunol. 2011;22:537–42.PubMedCrossRef
73.
Zurück zum Zitat Osborn DA, Sinn JK. Probiotics in infants for prevention of allergic disease and food hypersensitivity. Cochrane Database Syst Rev. 2007;4:CD006475.PubMed Osborn DA, Sinn JK. Probiotics in infants for prevention of allergic disease and food hypersensitivity. Cochrane Database Syst Rev. 2007;4:CD006475.PubMed
74.
Zurück zum Zitat Dotterud CK, Storrø O, Johnsen R, Oien T. Probiotics in pregnant women to prevent allergic disease: a randomized, double-blind trial. Br J Dermatol. 2010;163:616–23.PubMedCrossRef Dotterud CK, Storrø O, Johnsen R, Oien T. Probiotics in pregnant women to prevent allergic disease: a randomized, double-blind trial. Br J Dermatol. 2010;163:616–23.PubMedCrossRef
75.
Zurück zum Zitat •• Doege K, Grajecki D, Zyriax BC, et al. Impact of maternal supplementation with probiotics during pregnancy on atopic eczema in childhood – a meta-analysis. Br J Nutr. 2012;107:1–6. Probiotics during pregnancy and their efficacy on prevention of atopic dermatitis in the newborn.PubMedCrossRef •• Doege K, Grajecki D, Zyriax BC, et al. Impact of maternal supplementation with probiotics during pregnancy on atopic eczema in childhood – a meta-analysis. Br J Nutr. 2012;107:1–6. Probiotics during pregnancy and their efficacy on prevention of atopic dermatitis in the newborn.PubMedCrossRef
76.
Zurück zum Zitat Wickens K, Black P, Stanley TV, et al. A protective effect of Lactobacillus rhamnosus HN001 against eczema in the first 2 years of life persists to age 4 years. Clin Exp Allergy. 2012;42:1071–9.PubMedCrossRef Wickens K, Black P, Stanley TV, et al. A protective effect of Lactobacillus rhamnosus HN001 against eczema in the first 2 years of life persists to age 4 years. Clin Exp Allergy. 2012;42:1071–9.PubMedCrossRef
77.
Zurück zum Zitat Pelucchi C, Chatenoud L, Turati F, et al. Probiotics supplementation during pregnancy or infancy for the prevention of atopic dermatitis: a meta-analysis. Epidemiology. 2012;23:402–14.PubMedCrossRef Pelucchi C, Chatenoud L, Turati F, et al. Probiotics supplementation during pregnancy or infancy for the prevention of atopic dermatitis: a meta-analysis. Epidemiology. 2012;23:402–14.PubMedCrossRef
78.
Zurück zum Zitat Williams HC, Grindlay DJ. What's new in atopic eczema? An analysis of systematic reviews published in 2007 and 2008. Part 2. Disease prevention and treatment. Clin Exp Dermatol. 2010;35:223–7.PubMedCrossRef Williams HC, Grindlay DJ. What's new in atopic eczema? An analysis of systematic reviews published in 2007 and 2008. Part 2. Disease prevention and treatment. Clin Exp Dermatol. 2010;35:223–7.PubMedCrossRef
79.
Zurück zum Zitat van der Aa LB, Lutter R, Heymans HS, et al. Synbad Study Group. No detectable beneficial systemic immunomodulatory effects of a specific synbiotic mixture in infants with atopic dermatitis. Clin Exp Allergy. 2012;42:531–9.PubMedCrossRef van der Aa LB, Lutter R, Heymans HS, et al. Synbad Study Group. No detectable beneficial systemic immunomodulatory effects of a specific synbiotic mixture in infants with atopic dermatitis. Clin Exp Allergy. 2012;42:531–9.PubMedCrossRef
80.
Zurück zum Zitat van der Aa LB, van Aalderen WM, Heymans HS, et al. Synbad Study Group. Synbiotics prevent asthma-like symptoms in infants with atopic dermatitis. Allergy. 2011;66:170–7.PubMedCrossRef van der Aa LB, van Aalderen WM, Heymans HS, et al. Synbad Study Group. Synbiotics prevent asthma-like symptoms in infants with atopic dermatitis. Allergy. 2011;66:170–7.PubMedCrossRef
81.
Zurück zum Zitat Wu KG, Li TH, Peng HJ. Lactobacillus salivarius plus fructo-oligosaccharide is superior to fructo-oligosaccharide alone for treating children with moderate to severe atopic dermatitis: a double-blind, randomized, clinical trial of efficacy and safety. Br J Dermatol. 2012;166:129–36.PubMedCrossRef Wu KG, Li TH, Peng HJ. Lactobacillus salivarius plus fructo-oligosaccharide is superior to fructo-oligosaccharide alone for treating children with moderate to severe atopic dermatitis: a double-blind, randomized, clinical trial of efficacy and safety. Br J Dermatol. 2012;166:129–36.PubMedCrossRef
82.
Zurück zum Zitat Han Y, Kim B, Ban J, et al. A randomized trial of Lactobacillus plantarum CJLP133 for the treatment of atopic dermatitis. Pediatr Allergy Immunol. 2012;23:667–73.PubMedCrossRef Han Y, Kim B, Ban J, et al. A randomized trial of Lactobacillus plantarum CJLP133 for the treatment of atopic dermatitis. Pediatr Allergy Immunol. 2012;23:667–73.PubMedCrossRef
83.
Zurück zum Zitat Gore C, Custovic A, Tannock GW, et al. Treatment and secondary prevention effects of the probiotics Lactobacillus paracasei or Bifidobacterium lactis on early infant eczema: randomized controlled trial with follow-up until age 3 years. Clin Exp Allergy. 2012;42:112–22.PubMedCrossRef Gore C, Custovic A, Tannock GW, et al. Treatment and secondary prevention effects of the probiotics Lactobacillus paracasei or Bifidobacterium lactis on early infant eczema: randomized controlled trial with follow-up until age 3 years. Clin Exp Allergy. 2012;42:112–22.PubMedCrossRef
84.
Zurück zum Zitat •• Bath-Hextall FJ, Jenkinson C, Humphreys R, Williams HC. Dietary supplements for established atopic eczema. Cochrane Database Syst Rev. 2012;2:CD005205. Probiotics during pregnancy and their efficacy on prevention of atopic dermatitis in the newborn.PubMed •• Bath-Hextall FJ, Jenkinson C, Humphreys R, Williams HC. Dietary supplements for established atopic eczema. Cochrane Database Syst Rev. 2012;2:CD005205. Probiotics during pregnancy and their efficacy on prevention of atopic dermatitis in the newborn.PubMed
85.
Zurück zum Zitat Savino F, Cordisco L, Tarasco V, et al. Lactobacillus reuteri DSM 17938 in infantile colic: a randomized, double-blind, placebo-controlled trial. Pediatrics. 2010;126:e526–33.PubMedCrossRef Savino F, Cordisco L, Tarasco V, et al. Lactobacillus reuteri DSM 17938 in infantile colic: a randomized, double-blind, placebo-controlled trial. Pediatrics. 2010;126:e526–33.PubMedCrossRef
86.
Zurück zum Zitat Szajewska H, Gyrczuk E, Horvath A. Lactobacillus reuteri DSM 17938 for the management of infantile colic in breastfed infants: a randomized, double-blind, placebo-controlled trial. J Pediatr. 2013;162:257–62.PubMedCrossRef Szajewska H, Gyrczuk E, Horvath A. Lactobacillus reuteri DSM 17938 for the management of infantile colic in breastfed infants: a randomized, double-blind, placebo-controlled trial. J Pediatr. 2013;162:257–62.PubMedCrossRef
87.
Zurück zum Zitat Dupont C, Rivero M, Grillon C, et al. Alpha-lactalbumin-enriched and probiotic-supplemented infant formula in infants with colic: growth and gastrointestinal tolerance. Eur J Clin Nutr. 2010;64:765–7.PubMedCrossRef Dupont C, Rivero M, Grillon C, et al. Alpha-lactalbumin-enriched and probiotic-supplemented infant formula in infants with colic: growth and gastrointestinal tolerance. Eur J Clin Nutr. 2010;64:765–7.PubMedCrossRef
88.
Zurück zum Zitat Di Pierro F, Donato G, Fomia F, et al. Preliminary pediatric clinical evaluation of the oral probiotic Streptococcus salivarius K12 in preventing recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes and recurrent acute otitis media. Int J Gen Med. 2012;5:991–7.PubMedCrossRef Di Pierro F, Donato G, Fomia F, et al. Preliminary pediatric clinical evaluation of the oral probiotic Streptococcus salivarius K12 in preventing recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes and recurrent acute otitis media. Int J Gen Med. 2012;5:991–7.PubMedCrossRef
89.
Zurück zum Zitat Picaud JC, Chapalain V, Paineau D, et al. Incidence of infectious diseases in infants fed follow-on formula containing synbiotics: an observational study. Acta Paediatr. 2010;99:1695–700.PubMedCrossRef Picaud JC, Chapalain V, Paineau D, et al. Incidence of infectious diseases in infants fed follow-on formula containing synbiotics: an observational study. Acta Paediatr. 2010;99:1695–700.PubMedCrossRef
90.
Zurück zum Zitat Maldonado J, Cañabate F, Sempere L, et al. Human milk probiotic Lactobacillus fermentum CECT5716 reduces the incidence of gastrointestinal and upper respiratory tract infections in infants. J Pediatr Gastroenterol Nutr. 2012;54:55–61.PubMedCrossRef Maldonado J, Cañabate F, Sempere L, et al. Human milk probiotic Lactobacillus fermentum CECT5716 reduces the incidence of gastrointestinal and upper respiratory tract infections in infants. J Pediatr Gastroenterol Nutr. 2012;54:55–61.PubMedCrossRef
91.
Zurück zum Zitat Kukkonen K, Savilahti E, Haahtela T, et al. Long-term safety and impact on infection rates of postnatal probiotic and prebiotic (synbiotic) treatment: randomized, double-blind, placebo-controlled trial. Pediatrics. 2008;122:8–12.PubMedCrossRef Kukkonen K, Savilahti E, Haahtela T, et al. Long-term safety and impact on infection rates of postnatal probiotic and prebiotic (synbiotic) treatment: randomized, double-blind, placebo-controlled trial. Pediatrics. 2008;122:8–12.PubMedCrossRef
92.
Zurück zum Zitat van Stuijvenberg M, Eisses AM, Grüber C, et al. Do prebiotics reduce the number of fever episodes in healthy children in their first year of life: a randomised controlled trial. Br J Nutr. 2011;106:1740–8.PubMedCrossRef van Stuijvenberg M, Eisses AM, Grüber C, et al. Do prebiotics reduce the number of fever episodes in healthy children in their first year of life: a randomised controlled trial. Br J Nutr. 2011;106:1740–8.PubMedCrossRef
93.
Zurück zum Zitat Popova M, Molimard P, Courau S, et al. Beneficial effects of probiotics in upper respiratory tract infections and their mechanical actions to antagonize pathogens. J Appl Microbiol. 2012;113:1305–18.PubMedCrossRef Popova M, Molimard P, Courau S, et al. Beneficial effects of probiotics in upper respiratory tract infections and their mechanical actions to antagonize pathogens. J Appl Microbiol. 2012;113:1305–18.PubMedCrossRef
94.
Zurück zum Zitat Taipale T, Pienihäkkinen K, Isolauri E, et al. Bifidobacterium animalis subsp. lactis BB-12 in reducing the risk of infections in infancy. Br J Nutr. 2011;105:409–16.PubMedCrossRef Taipale T, Pienihäkkinen K, Isolauri E, et al. Bifidobacterium animalis subsp. lactis BB-12 in reducing the risk of infections in infancy. Br J Nutr. 2011;105:409–16.PubMedCrossRef
95.
Zurück zum Zitat Rautava S, Salminen S, Isolauri E. Specific probiotics in reducing the risk of acute infections in infancy – a randomised, double-blind, placebo-controlled study. Br J Nutr. 2009;101:1722–6.PubMedCrossRef Rautava S, Salminen S, Isolauri E. Specific probiotics in reducing the risk of acute infections in infancy – a randomised, double-blind, placebo-controlled study. Br J Nutr. 2009;101:1722–6.PubMedCrossRef
96.
Zurück zum Zitat Skovbjerg S, Roos K, Holm SE, et al. Spray bacteriotherapy decreases middle ear fluid in children with secretory otitis media. Arch Dis Child. 2009;94:92–8.PubMedCrossRef Skovbjerg S, Roos K, Holm SE, et al. Spray bacteriotherapy decreases middle ear fluid in children with secretory otitis media. Arch Dis Child. 2009;94:92–8.PubMedCrossRef
97.
Zurück zum Zitat Hatakka K, Blomgren K, Pohjavuori S, et al. Treatment of acute otitis media with probiotics in otitis-prone children – a double-blind, placebo-controlled randomised study. Clin Nutr. 2007;26:314–21.PubMedCrossRef Hatakka K, Blomgren K, Pohjavuori S, et al. Treatment of acute otitis media with probiotics in otitis-prone children – a double-blind, placebo-controlled randomised study. Clin Nutr. 2007;26:314–21.PubMedCrossRef
98.
Zurück zum Zitat Stecksén-Blicks C, Sjöström I, Twetman S. Effect of long-term consumption of milk supplemented with probiotic lactobacilli and fluoride on dental caries and general health in preschool children: a cluster-randomized study. Caries Res. 2009;43:374–81.PubMedCrossRef Stecksén-Blicks C, Sjöström I, Twetman S. Effect of long-term consumption of milk supplemented with probiotic lactobacilli and fluoride on dental caries and general health in preschool children: a cluster-randomized study. Caries Res. 2009;43:374–81.PubMedCrossRef
99.
Zurück zum Zitat Niittynen L, Pitkäranta A, Korpela R. Probiotics and otitis media in children. Int J Pediatr Otorhinolaryngol. 2012;76:465–70.PubMedCrossRef Niittynen L, Pitkäranta A, Korpela R. Probiotics and otitis media in children. Int J Pediatr Otorhinolaryngol. 2012;76:465–70.PubMedCrossRef
100.
Zurück zum Zitat Weichert S, Schroten H, Adam R. The role of prebiotics and probiotics in prevention and treatment of childhood infectious diseases. Pediat Infect Dis J. 2012;31:859–62.CrossRef Weichert S, Schroten H, Adam R. The role of prebiotics and probiotics in prevention and treatment of childhood infectious diseases. Pediat Infect Dis J. 2012;31:859–62.CrossRef
101.
Zurück zum Zitat Sazawal S, Dhingra U, Hiremath G, et al. Prebiotic and probiotic fortified milk in prevention of morbidities among children: community-based, randomized, double-blind, controlled trial. PLoS One. 2010;5:e12164.PubMedCrossRef Sazawal S, Dhingra U, Hiremath G, et al. Prebiotic and probiotic fortified milk in prevention of morbidities among children: community-based, randomized, double-blind, controlled trial. PLoS One. 2010;5:e12164.PubMedCrossRef
102.
Zurück zum Zitat Hao Q, Lu Z, Dong BR, et al. Probiotics for preventing acute upper respiratory tract infections. Cochrane Database Syst Rev. 2011;9:CD006895.PubMed Hao Q, Lu Z, Dong BR, et al. Probiotics for preventing acute upper respiratory tract infections. Cochrane Database Syst Rev. 2011;9:CD006895.PubMed
103.
Zurück zum Zitat Salvini FJ, Riva E, Salvatici E, et al. A specific prebiotic mixture added to starting infant formula has long-lasting bifidogenic effects. J Nutr. 2011;141:1335–9.PubMedCrossRef Salvini FJ, Riva E, Salvatici E, et al. A specific prebiotic mixture added to starting infant formula has long-lasting bifidogenic effects. J Nutr. 2011;141:1335–9.PubMedCrossRef
104.
Zurück zum Zitat Stam J, van Stuijvenberg M, Garssen J, et al. A mixture of three prebiotics does not affect vaccine specific antibody responses in healthy term infants in the first year of life. Vaccine. 2011;29:7766–72.PubMedCrossRef Stam J, van Stuijvenberg M, Garssen J, et al. A mixture of three prebiotics does not affect vaccine specific antibody responses in healthy term infants in the first year of life. Vaccine. 2011;29:7766–72.PubMedCrossRef
105.
Zurück zum Zitat Hong P, Ninonuevo MR, Lee B, et al. Human milk oligosaccharides reduce HIV-1-gp120 binding to dendritic cell-specific ICAM3-grabbing non-integrin (DC-SIGN). Br J Nutr. 2009;101:482–6.PubMedCrossRef Hong P, Ninonuevo MR, Lee B, et al. Human milk oligosaccharides reduce HIV-1-gp120 binding to dendritic cell-specific ICAM3-grabbing non-integrin (DC-SIGN). Br J Nutr. 2009;101:482–6.PubMedCrossRef
106.
Zurück zum Zitat Sanz-Penella JM, Frontela C, Ros G, et al. Application of bifidobacterial phytases in infant cereals: effect on phytate contents and mineral dialyzability. J Agric Food Chem. 2012;60:11787–892.PubMedCrossRef Sanz-Penella JM, Frontela C, Ros G, et al. Application of bifidobacterial phytases in infant cereals: effect on phytate contents and mineral dialyzability. J Agric Food Chem. 2012;60:11787–892.PubMedCrossRef
107.
Zurück zum Zitat Capozzi V, Russo P, Dueñas MT, et al. Lactic acid bacteria producing B-group vitamins: a great potential for functional cereals products. Appl Microbiol Biotechnol. 2012;96:1383–94.PubMedCrossRef Capozzi V, Russo P, Dueñas MT, et al. Lactic acid bacteria producing B-group vitamins: a great potential for functional cereals products. Appl Microbiol Biotechnol. 2012;96:1383–94.PubMedCrossRef
108.
Zurück zum Zitat • Shanahan F. A commentary on the safety of probiotics. Gastroenterol Clin North Am. 2012;41:869–76. Are probiotics really safe?.PubMedCrossRef • Shanahan F. A commentary on the safety of probiotics. Gastroenterol Clin North Am. 2012;41:869–76. Are probiotics really safe?.PubMedCrossRef
109.
Zurück zum Zitat Allen SJ, Jordan S, Storey M, et al. Dietary supplementation with lactobacilli and bifidobacteria is well tolerated and not associated with adverse events during late pregnancy and early infancy. J Nutr. 2010;140:483–8.PubMedCrossRef Allen SJ, Jordan S, Storey M, et al. Dietary supplementation with lactobacilli and bifidobacteria is well tolerated and not associated with adverse events during late pregnancy and early infancy. J Nutr. 2010;140:483–8.PubMedCrossRef
110.
Zurück zum Zitat Martín-Muñoz MF, Fortuni M, Caminoa M, et al. Anaphylactic reaction to probiotics. Cow's milk and hen's egg allergens in probiotic compounds. Pediatr Allergy Immunol. 2012;23:778–84.PubMedCrossRef Martín-Muñoz MF, Fortuni M, Caminoa M, et al. Anaphylactic reaction to probiotics. Cow's milk and hen's egg allergens in probiotic compounds. Pediatr Allergy Immunol. 2012;23:778–84.PubMedCrossRef
111.
Zurück zum Zitat •• Dai M, Lu J, Wang Y, et al. In vitro development and transfer of resistance to chlortetracycline in Bacillus subtilis. J Microbiol. 2012;50:807–12. The danger of transfer of plasmid resistance with some probiotic strains.PubMedCrossRef •• Dai M, Lu J, Wang Y, et al. In vitro development and transfer of resistance to chlortetracycline in Bacillus subtilis. J Microbiol. 2012;50:807–12. The danger of transfer of plasmid resistance with some probiotic strains.PubMedCrossRef
112.
Zurück zum Zitat Hennequin C, Kauffmann-Lacroix C, Jobert A, et al. Possible role of catheters in Saccharomyces boulardii fungemia. Eur J Clin Microbiol Infect Dis. 2000;19:16–20.PubMedCrossRef Hennequin C, Kauffmann-Lacroix C, Jobert A, et al. Possible role of catheters in Saccharomyces boulardii fungemia. Eur J Clin Microbiol Infect Dis. 2000;19:16–20.PubMedCrossRef
113.
Zurück zum Zitat Venugopalan V, Shriner KA, Wong-Beringer A. Regulatory oversight and safety of probiotic use. Emerg Infect Dis. 2010;16:1661–5.PubMedCrossRef Venugopalan V, Shriner KA, Wong-Beringer A. Regulatory oversight and safety of probiotic use. Emerg Infect Dis. 2010;16:1661–5.PubMedCrossRef
114.
Zurück zum Zitat Manzoni P, De Luca D, Stronati M, et al. Prevention of nosocomial infections in neonatal intensive care units. Am J Perinatol. 2013;30:81–8.PubMedCrossRef Manzoni P, De Luca D, Stronati M, et al. Prevention of nosocomial infections in neonatal intensive care units. Am J Perinatol. 2013;30:81–8.PubMedCrossRef
115.
Zurück zum Zitat Weichert S, Schroten H, Adam R. The role of prebiotics and probiotics in prevention and treatment of childhood infectious diseases. Pediatr Infect Dis J. 2012;31:856–62.CrossRef Weichert S, Schroten H, Adam R. The role of prebiotics and probiotics in prevention and treatment of childhood infectious diseases. Pediatr Infect Dis J. 2012;31:856–62.CrossRef
116.
Zurück zum Zitat Mugambi MN, Musekiwa A, Lombard M, et al. Synbiotics, probiotics or prebiotics in infant formula for full term infants: a systematic review. Nutr J. 2012;11:81.PubMedCrossRef Mugambi MN, Musekiwa A, Lombard M, et al. Synbiotics, probiotics or prebiotics in infant formula for full term infants: a systematic review. Nutr J. 2012;11:81.PubMedCrossRef
Metadaten
Titel
Probiotics and Prebiotics in Infants and Children
verfasst von
Y. Vandenplas
E. De Greef
T. Devreker
G. Veereman-Wauters
B. Hauser
Publikationsdatum
01.06.2013
Verlag
Current Science Inc.
Erschienen in
Current Infectious Disease Reports / Ausgabe 3/2013
Print ISSN: 1523-3847
Elektronische ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-013-0334-4

Weitere Artikel der Ausgabe 3/2013

Current Infectious Disease Reports 3/2013 Zur Ausgabe

PEDIATRIC INFECTIOUS DISEASES (I BROOK, SECTION EDITOR)

Long-Term Sequelae of Childhood Bacterial Meningitis

Tropical, Travel and Emerging Infections (L Chen, Section Editor)

Chronic Diarrhea in Travelers

Pediatric Infectious Diseases (I Brook, Section Editor)

Treatment and Prevention of Rotavirus Infection in Children

Pediatric Infectious Diseases (I Brook, Section Editor)

Reducing Central Line Infections in Pediatric and Neonatal Patients

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.